GIP and type 2 diabetes mellitus: Some of the most compelling evidence supporting the benefit of GIP/GLP-1R agonism comes from a 40-wk, head-to-head study showing the superiority of tirzepatide over semaglutide for glucose and body weight reduction in patients with T2D (58).